MCID: UVL004
MIFTS: 60

Uveal Melanoma malady

Categories: Genetic diseases, Eye diseases, Rare diseases, Cancer diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Uveal Melanoma

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 45NCIt, 50Novoseek, 54Orphanet, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Uveal Melanoma:

Name: Uveal Melanoma 11 54 50 39 13 68
Malignant Melanoma of Choroid 68
Malignant Melanoma of Iris 68
Choroidal Melanoma 54
 
Melanoma of Uvea 11
Melanoma, Uveal 24
Iris Melanoma 54

Characteristics:

Orphanet epidemiological data:

54
uveal melanoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly


Classifications:

Orphanet: 54 
Rare eye diseases


External Ids:

Disease Ontology11 DOID:6039
MeSH39 C536494
NCIt45 C7712
Orphanet54 ORPHA39044
MESH via Orphanet40 C536494
UMLS via Orphanet69 C0220633, C0346373
ICD10 via Orphanet31 C69.3

Summaries for Uveal Melanoma

About this section
Wikipedia:71 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

MalaCards based summary: Uveal Melanoma, also known as malignant melanoma of choroid, is related to posterior uveal melanoma and malignant iris melanoma, and has symptoms including Array, Array and Array. An important gene associated with Uveal Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways are Transcription_Transcription factor Tubby signaling pathways and Arf6 signaling events. Affiliated tissues include eye, retina and liver, and related mouse phenotypes are Decreased substrate adherent cell growth and Decreased cell migration.

Disease Ontology:11 A uveal cancer that has material basis in uvea pigment cells.

Related Diseases for Uveal Melanoma

About this section

Diseases in the Uveal Melanoma family:

Melanoma, Uveal 2 Melanoma, Uveal 1
Posterior Uveal Melanoma

Diseases related to Uveal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 102)
idRelated DiseaseScoreTop Affiliating Genes
1posterior uveal melanoma12.2
2malignant iris melanoma12.1
3necrotic uveal melanoma12.1
4malignant choroid melanoma12.1
5melanoma, uveal 212.0
6melanoma, uveal 112.0
7mixed cell uveal melanoma12.0
8ocular melanoma11.4
9tumor predisposition syndrome11.2
10melanoma11.1
11uveal epithelioid cell melanoma11.0
12x-linked intellectual disability, shashi type10.4GNA11, GNAQ
13house allergic alveolitis10.4CDK4, CDKN2A, MET
14well-differentiated thymic neuroendocrine carcinoma10.4BAP1, BRAF
15melanoma, cutaneous malignant 810.4MITF, TYR
16aortic aneurysm10.4CDK4, CDKN2A, VEGFC
17vulval paget's disease10.4CDKN2A, NRAS, TYR
18integumentary system benign neoplasm10.3CDK4, CDKN2A, GNA11, GNAQ
19lung mucoepidermoid carcinoma10.3BRAF, MITF, NRAS
20post-surgical hypoinsulinemia10.3CDK4, CDKN2A, GNA11, GNAQ
21thoracic outlet syndrome10.3CDK4, CDKN2A, GNA11, GNAQ
22stomach diverticulosis10.3BRAF, S100B, TYR
23ossifying fibromyxoid tumor10.3CDK4, CDKN2A, NRAS
24monostotic fibrous dysplasia10.3BRAF, CDKN2A, S100B
25epilepsy, progressive myoclonic 510.3MITF, TYR
26mediastinitis10.3MITF, PMEL
27gallbladder pleomorphic giant cell adenocarcinoma10.3CDKN2A, GNA11, GNAQ, NRAS
28adult epithelioid sarcoma10.3CDKN2A, GNA11, GNAQ, NRAS
29acute disseminated encephalomyelitis10.3BRAF, CDKN2A, MET, NRAS
30pathologic nystagmus10.3CDKN2A, MITF, S100B
31craniosynostosis 610.3MITF, PMEL, TYR
32sengers syndrome10.3CDKN2A, MET, S100B
33onychocytic matricoma10.3IGF1R, MMP2, S100B
34neurocutaneous melanosis, somatic10.3MC1R, NRAS, TYR
35mitochondrial encephalomyopathy10.3CDKN2A, MC1R, MMP2
36non-distal monosomy 10q10.3BRAF, CDKN2A, MET, NRAS
37glucose-6-phosphate translocase deficiency10.3CDK4, CDKN2A, IGF1R, MET
38facial hemiatrophy10.3BAP1, CDKN2A, MC1R, NRAS
39maxillary sinus cholesteatoma10.3CDKN2A, MMP2, VEGFC
40metagonimiasis10.3MET, MMP2, VEGFC
41traumatic brain injury10.3CDKN2A, MMP2, VEGFC
42verrucous papilloma10.3MITF, NRAS, PMEL, TYR
43hypotrichosis 810.3CDK4, CDKN2A, IGF1R, MET, MMP2
44grade iii astrocytoma10.3CDK4, CDKN2A, MMP2, S100B
45vulvar proximal-type epithelioid sarcoma10.3BAP1, CDKN2A, MET
46leukoencephalopathy palmoplantar keratoderma10.3MC1R, MITF, MMP2, S100B
47glomeruloid hemangioma10.3BRAF, CDK4, CDKN2A, NRAS, TIMP3
48facial nerve disease10.3BAP1, GNA11, GNAQ, NRAS, S100B
49hypogonadotropic hypogonadism 20 with or without anosmia10.3CDK4, CDKN2A, MMP2, VEGFC
50fallopian tube adenofibroma10.3BAP1, GNA11, GNAQ, NRAS, S100B

Graphical network of the top 20 diseases related to Uveal Melanoma:



Diseases related to uveal melanoma

Symptoms & Phenotypes for Uveal Melanoma

About this section

Human phenotypes related to Uveal Melanoma:

 54 64 (show all 18)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual loss64 54 Very frequent (99-80%) HP:0000572
2 abnormality of the fundus54 Very frequent (99-80%)
3 choroidal melanoma64 54 Very frequent (99-80%) HP:0012054
4 retinal detachment64 54 Frequent (79-30%) HP:0000541
5 iris melanoma64 54 Frequent (79-30%) HP:0011524
6 ciliary body melanoma64 54 Frequent (79-30%) HP:0012055
7 abnormality of refraction64 54 Occasional (29-5%) HP:0000539
8 vitreous hemorrhage64 54 Occasional (29-5%) HP:0007902
9 increased intraocular pressure64 54 Occasional (29-5%) HP:0007906
10 inferior lens subluxation64 54 Occasional (29-5%) HP:0008494
11 zonular cataract64 54 Occasional (29-5%) HP:0010920
12 mydriasis64 54 Occasional (29-5%) HP:0011499
13 metamorphopsia64 54 Occasional (29-5%) HP:0012508
14 photopsia64 54 Occasional (29-5%) HP:0030786
15 abnormal visual accommodation64 54 Occasional (29-5%) HP:0030800
16 inflammatory abnormality of the eye64 54 Very rare (<4-1%) HP:0100533
17 ocular pain64 54 Very rare (<4-1%) HP:0200026
18 intraocular melanoma64 HP:0007716

GenomeRNAi Phenotypes related to Uveal Melanoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00193-A-310.3BRAF, CDK4, IGF1R, MET
2GR00055-A-110.2BRAF, CDK4, IGF1R, MET, VEGFC
3GR00366-A-8410.0CDH5, GNA11, IGF1R, TIMP3

MGI Mouse Phenotypes related to Uveal Melanoma according to GeneCards Suite gene sharing:

41 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537710.1BRAF, GNA11, GNAQ, IGF1R, MC1R, MITF
2MP:000536710.0BRAF, CDK4, GNA11, GNAQ, MET, TIMP3
3MP:00053719.9GNA11, GNAQ, IGF1R, MC1R, MET, MITF
4MP:00053819.8BAP1, BRAF, CDK4, CDKN2A, IGF1R, MET
5MP:00053909.8BRAF, CDKN2A, GNA11, GNAQ, IGF1R, MITF
6MP:00020069.7BAP1, BRAF, CDK4, CDKN2A, IGF1R, MC1R
7MP:00053809.7BAP1, BRAF, CDH5, CDK4, CDKN2A, IGF1R
8MP:00053829.7BRAF, CDH5, GNA11, GNAQ, IGF1R, MC1R
9MP:00030129.6BAP1, CDKN2A, MC1R, MET, MITF, NRAS
10MP:00011869.6BRAF, CDK4, CDKN2A, GNA11, GNAQ, MC1R
11MP:00053889.5BAP1, BRAF, CDKN2A, CYSLTR2, GNA11, GNAQ
12MP:00053699.5BAP1, BRAF, CDK4, CDKN2A, GNA11, GNAQ
13MP:00053709.5BRAF, CDH5, CDK4, CDKN2A, GNA11, IGF1R
14MP:00028739.4BRAF, CDH5, CDK4, GNA11, GNAQ, MET
15MP:00053919.4BRAF, CDH5, CDK4, CDKN2A, MET, MITF
16MP:00053849.2BAP1, BRAF, CDH5, CDK4, CDKN2A, IGF1R
17MP:00053869.2BRAF, CDK4, CDKN2A, GNA11, GNAQ, IGF1R
18MP:00053799.1BAP1, BRAF, CDH5, CDK4, CDKN2A, GNA11
19MP:00053788.9BAP1, BRAF, CDH5, CDK4, CDKN2A, GNA11
20MP:00053858.9BAP1, BRAF, CDH5, CDK4, CDKN2A, CYSLTR2
21MP:00107688.8BAP1, BRAF, CDH5, CDK4, CDKN2A, GNA11
22MP:00053978.8BAP1, BRAF, CDH5, CDK4, CDKN2A, GNA11
23MP:00107718.7BAP1, BRAF, CDH5, CDK4, CDKN2A, CYSLTR2
24MP:00053878.5BAP1, BRAF, CDH5, CDK4, CDKN2A, CYSLTR2
25MP:00053768.4BAP1, BRAF, CDH5, CDK4, CDKN2A, CYSLTR2

Drugs & Therapeutics for Uveal Melanoma

About this section

Drugs for Uveal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 179)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RanibizumabapprovedPhase 4, Phase 2, Phase 3486347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
2
Triamcinoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3510124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
3triamcinolone acetonidePhase 4, Phase 2, Phase 3510
4Triamcinolone diacetatePhase 4, Phase 2, Phase 3510
5Triamcinolone hexacetonidePhase 4, Phase 2, Phase 3510
6Angiogenesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 14257
7Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 113086
8Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 113168
9Angiogenesis Modulating AgentsPhase 4, Phase 2, Phase 3, Phase 14185
10Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 310729
11glucocorticoidsPhase 4, Phase 2, Phase 35103
12HormonesPhase 4, Phase 2, Phase 3, Phase 114415
13Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 113180
14
Dacarbazineapproved, investigationalPhase 3, Phase 2, Phase 16884342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
15
MelphalanapprovedPhase 3, Phase 2729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
16
PembrolizumabapprovedPhase 3, Phase 2, Phase 15071374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
17
FotemustineexperimentalPhase 310
Synonyms:
(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
 
Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate
Fotemustina
Fotemustinum
18Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 14603
19ImmunoglobulinsPhase 3, Phase 2, Phase 1, Early Phase 16394
20Antibodies, MonoclonalPhase 3, Phase 2, Phase 1, Early Phase 14039
21AntibodiesPhase 3, Phase 2, Phase 1, Early Phase 16394
22Alkylating AgentsPhase 3, Phase 2, Phase 14827
23Liver ExtractsPhase 3, Phase 2, Phase 1, Early Phase 14067
24
ImidazolePhase 3, Phase 233288-32-4795
Synonyms:
1,3-Diaza-2,4-cyclopentadiene
1,3-Diazole
1H-Imidazole
Glyoxalin
Glyoxaline
 
IMD
Imidazol
Iminazole
Imutex
Miazole
Pyrro(b)monazole
{Pyrro[b]monazole}
25VaccinesPhase 3, Phase 2, Phase 16611
26
CisplatinapprovedPhase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
27
Sorafenibapproved, investigationalPhase 2, Phase 1700284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
28
Sunitinibapproved, investigationalPhase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
29
TamoxifenapprovedPhase 239010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
30
Bevacizumabapproved, investigationalPhase 22020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
31
Temozolomideapproved, investigationalPhase 2, Phase 171185622-93-15394
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
85622-93-1
AC-758
AC1L1K9B
BIDD:GT0204
BRN 5547136
Bio-0147
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
 
M-39831
MB 39831
MLS000759447
MLS001424028
MLS002701861
Methazolastone
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC-362856
NSC362856
SAM001246636
SMR000466338
STK623541
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
TL8005593
TMZ
TMZ-Bioshuttle
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
Témozolomide
UNII-YF1K15M17Y
ZINC01482184
m & b 39831
temozolomide
32
Sirolimusapproved, investigationalPhase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
33
SomatostatinapprovedPhase 2, Phase 123738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
34
Vincristineapproved, investigationalPhase 29222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
35
Ethiodized oilapprovedPhase 2968008-53-5
Synonyms:
 
EOE 13
36
EverolimusapprovedPhase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
37
Miconazoleapproved, investigational, vet_approvedPhase 2370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
38
LomustineapprovedPhase 28413010-47-43950
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
BRN 2125058
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
CHEMBL514
CID3950
CINU
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
Chloroethylcyclohexylnitrosourea
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
 
HMS2090A17
HSDB 6519
I06-0087
ICIG 1109
LS-728
Lomustina
Lomustina [INN-Spanish]
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
MolPort-001-768-818
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI-C04740
NCI60_041743
NCIMech_000220
NPFAPI-06
NSC 79037
NSC-79037
NSC79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
lomustine
medac Brand of Lomustine
39
Bortezomibapproved, investigationalPhase 2807179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
40
PancrelipaseapprovedPhase 297053608-75-6
Synonyms:
1,4-alpha-D- glucan glucanohydrolase
PA
 
Pancreatic alpha-amylase precursor
Pancrelipase (amylase
lipase
protease)
41
TrametinibapprovedPhase 2, Phase 1131871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
42
FludarabineapprovedPhase 2, Phase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
43
Vorinostatapproved, investigationalPhase 2, Early Phase 1247149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
44
AldesleukinapprovedPhase 1, Phase 240585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
45
CarboplatinapprovedPhase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
46
Peginterferon alfa-2bapprovedPhase 230799210-65-8, 215647-85-1
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
 
Peginterferon alfa-2b
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron (TN)
Unitron PEG
47
Aluminum hydroxideapprovedPhase 221021645-51-2
Synonyms:
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
 
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
48
Paclitaxelapproved, vet_approvedPhase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
49
Leuprolideapproved, investigationalPhase 229953714-56-03911, 657181
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
AC1L1GZK
AC1L9B44
AC1Q5OPO
AR-1G9354
C07612
CID3911
CID441410
D00989
D08113
Enantone
Enantone (TN)
I04-0109
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
L001094
 
L002030
Leuprolide
Leuprolide acetate
Leuprolide acetate (USAN)
Leuprorelin
Leuprorelin (INN)
Leuprorelin acetate (JAN)
Leuprorelina
Leuproreline
Leuprorelinum
Lupron (TN)
N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
NSC377526
NSC746847
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet
acetic acid
leuprolide
50
Valproic Acidapproved, investigationalPhase 232799-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico

Interventional clinical trials:

(show top 50)    (show all 135)
idNameStatusNCT IDPhase
1Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyUnknown statusNCT00540930Phase 4
2TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyActive, not recruitingNCT02379000Phase 4
3Treatment Of Radiation Retinopathy TrialUnknown statusNCT00811200Phase 2, Phase 3
4Collaborative Ocular Melanoma Study (COMS)Unknown statusNCT00000124Phase 3
5Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)CompletedNCT01974752Phase 3
6Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaCompletedNCT00324727Phase 3
7Dendritic Cells Plus Autologous Tumor RNA in Uveal MelanomaRecruitingNCT01983748Phase 3
8The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver MetastasesRecruitingNCT01785316Phase 3
9Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular MelanomaRecruitingNCT02678572Phase 3
10Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal MelanomaActive, not recruitingNCT02843386Phase 3
11Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye MelanomaTerminatedNCT00110123Phase 3
12Vaccine Therapy in Treating Patients With Melanoma of the EyeTerminatedNCT00036816Phase 3
13A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal MelanomaUnknown statusNCT01377025Phase 2
14Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal MelanomaUnknown statusNCT01034787Phase 2
15Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the EyeUnknown statusNCT01217398Phase 2
16Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular MelanomaUnknown statusNCT00489944Phase 2
17Safety and Efficacy of Marqibo in Metastatic Malignant Uveal MelanomaCompletedNCT00506142Phase 2
18RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal MelanomaCompletedNCT01252251Phase 2
19Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic DisseminationCompletedNCT02517736Phase 2
20Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSFCompletedNCT00661622Phase 2
21Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By SurgeryCompletedNCT00738361Phase 2
22Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01143402Phase 2
23Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01413191Phase 2
24Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the EyeCompletedNCT00329641Phase 2
25Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003339Phase 2
26Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2
27Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00027742Phase 2
28Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00334776Phase 2
29PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT00238329Phase 2
30Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT00020475Phase 2
31Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00089206Phase 2
32Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV MelanomaCompletedNCT00089219Phase 1, Phase 2
33Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00005815Phase 1, Phase 2
34Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye MelanomaCompletedNCT00003802Phase 2
35Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00032045Phase 2
36Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With MelanomaCompletedNCT00031733Phase 2
37Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00058279Phase 1, Phase 2
38Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT00072345Phase 2
39Melanoma Vaccine With Peptides and LeuprolideCompletedNCT00254397Phase 2
40Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2
41Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedNCT00085189Phase 2
42VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00450255Phase 2
43AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
44Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaCompletedNCT00288041Phase 2
45Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular MelanomaCompletedNCT00085306Phase 2
46Liver Transplantation and Uveal Malignant MelanomaCompletedNCT01311466Phase 2
47Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
48Taxoprexin® Treatment for Advanced Eye MelanomaCompletedNCT00244816Phase 2
49THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseCompletedNCT01355120Phase 2
50Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesRecruitingNCT02913417Phase 1, Phase 2

Search NIH Clinical Center for Uveal Melanoma


Cochrane evidence based reviews: uveal melanoma

Genetic Tests for Uveal Melanoma

About this section

Genetic tests related to Uveal Melanoma:

id Genetic test Affiliating Genes
1 Melanoma, Uveal24 GNA11, GNAQ

Anatomical Context for Uveal Melanoma

About this section

MalaCards organs/tissues related to Uveal Melanoma:

36
Eye, Retina, Liver, Testes, Endothelial, Monocytes, T cells

Publications for Uveal Melanoma

About this section

Articles related to Uveal Melanoma:

(show top 50)    (show all 567)
idTitleAuthorsYear
1
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. (27911126)
2017
2
The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression. (28124977)
2017
3
Prognostic value of apoptosis inducing factor in uveal melanoma. (28043154)
2017
4
Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma. (28056132)
2017
5
Immunotherapy of Uveal Melanoma: Vaccination Against Cancer. (27987156)
2017
6
Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. (28069617)
2017
7
Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma-Reply. (28056125)
2017
8
Lentiviral-mediated overexpression of KCTD12 inhibits the proliferation of human uveal melanoma OCM-1 cells. (28000887)
2017
9
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. (27507190)
2016
10
Prognostication of Uveal Melanoma: A Work in Progress. (27124594)
2016
11
Uveal Melanoma Mimicking Advanced Coats' Disease in a Young Patient. (27239453)
2016
12
SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. (26769193)
2016
13
Clinical application of genetic testing for posterior uveal melanoma. (27847622)
2016
14
Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. (27453764)
2016
15
Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. (27123562)
2016
16
More than Meets the Eye: Metastatic Uveal Melanoma. (27138426)
2016
17
Metastatic disease from uveal melanoma: treatment options and future prospects. (27574175)
2016
18
Uveal melanoma: relatively rare but deadly cancer. (27911450)
2016
19
Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations. (27116551)
2016
20
Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. (27513071)
2016
21
23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. (27638702)
2016
22
Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up. (27911584)
2016
23
WE-FG-BRA-10: Radiodosimetry of a Novel Alpha Particle Therapy Targeted to Uveal Melanoma: Absorbed Dose to Organs in Mice. (28048872)
2016
24
In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma. (27790127)
2016
25
Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. (27565163)
2016
26
The genetics of uveal melanoma: current insights. (27660484)
2016
27
Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. (27123792)
2016
28
P2RX7-V3 is a novel oncogene that promotes tumorigenesis in uveal melanoma. (27468714)
2016
29
Nanomedicine in the application of uveal melanoma. (27588278)
2016
30
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. (27476772)
2016
31
BRAF V600E-dependent role of autophagy in uveal melanoma. (27928645)
2016
32
Genetic markers of pigmentation are novel risk loci for uveal melanoma. (27499155)
2016
33
Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma. (27128983)
2016
34
Expression of EphA2 in Metastatic and Non-Metastatic Primary Uveal Melanoma]. (26854480)
2016
35
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. (26683228)
2016
36
Proton therapy for the management of uveal melanoma and other ocular tumors. (27558251)
2016
37
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma. (27532663)
2016
38
Genetic Variants of the BTNL2 Gene in Uveal Melanoma. (27533527)
2016
39
Novel mouse model for primary uveal melanoma: a pilot study. (27505446)
2016
40
Assessing Prognosis in Uveal Melanoma. (27218785)
2016
41
PAUPAR lncRNA suppresses tumourigenesis by H3K4 demethylation in uveal melanoma. (27214741)
2016
42
Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis). (28018010)
2016
43
Oncogenic role of microRNAa8920a in human uveal melanoma. (27356499)
2016
44
ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. (27546281)
2016
45
Two-year patient-reported outcomes following treatment of uveal melanoma. (27589051)
2016
46
Overexpression of Annexin II Receptor-Induced Autophagy Protects Against Apoptosis in Uveal Melanoma Cells. (27183438)
2016
47
p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma. (27584665)
2016
48
Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma: Anti-VEGFs versus corticosteroids for radiation maculopathy. (27163234)
2016
49
Analysis of caveolin-1 and phosphoinositol-3 kinase expression in primary uveal melanomas. (26590370)
2016
50
HIC1 modulates uveal melanoma progression by activating lncRNA-numb. (27449031)
2016

Variations for Uveal Melanoma

About this section

Copy number variations for Uveal Melanoma from CNVD:

6 (show all 33)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11332011124300000Copy numberUveal melanoma
2159781120700000121100000NomalNOTCH2Uveal melanoma
32174211610000020300000NomalNBL1Uveal melanoma
43219713440000046500000NomalMYCBPUveal melanoma
53219813440000046500000NomalPTAFRUveal melanoma
63359114650000051300000NomalMUTYHUveal melanoma
73519716090000084700000NomalRPE65Uveal melanoma
8375171920000012600000NomalMFN2Uveal melanoma
916606831199501827Copy numberUveal melanoma
101681753127700000131500000LossRhoUveal melanoma
111700483150400000153500000LossMMEUveal melanoma
12172555318400000104400000LossCPOUveal melanoma
131734443193800000199501827LossOPA1Uveal melanoma
1417474333210000043600000LossCTNNB1Uveal melanoma
1517539433930000043600000LossMLH1Uveal melanoma
1617573534360000051400000LossSEMA3BUveal melanoma
1717757035850000063700000LossFHITUveal melanoma
1817891038180000083700000LossROBO1Uveal melanoma
191791803870000011500000LossFANCD2Uveal melanoma
201791813870000011500000LossVHLUveal melanoma
2120364161170899992Copy numberUveal melanoma
222056396130400000131300000NomalCTGFUveal melanoma
232077596160900000164400000NomalIGF2RUveal melanoma
24209014623000004100000NomalUveal melanoma
2520904562350000026100000NomalDCDC2Uveal melanoma
2621024062990000045200000NomalRUNX2Uveal melanoma
2721230963680000040600000NomalCDKN1AUveal melanoma
282327468119200000122500000GainMYCUveal melanoma
292337728127300000140000000GainDDEF1Uveal melanoma
3023808982970000038500000NomalNRG1Uveal melanoma
31240056845200000146274826Copy numberUveal melanoma
32240078196792002467921999GainGDF-15Uveal melanoma
3324062485280000055600000GainRP1Uveal melanoma

Expression for genes affiliated with Uveal Melanoma

About this section
Search GEO for disease gene expression data for Uveal Melanoma.

Pathways for genes affiliated with Uveal Melanoma

About this section

Pathways related to Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 27)
idSuper pathwaysScoreTop Affiliating Genes
110.2GNA11, GNAQ, NRAS
210.2GNA11, GNAQ, MET
310.1GNA11, GNAQ, MMP2
410.1BRAF, GNA11, GNAQ
510.0IGF1R, MMP2, TIMP3
6
Show member pathways
10.0BRAF, GNA11, GNAQ, NRAS
7
Show member pathways
10.0BRAF, CDK4, CDKN2A, NRAS
89.9BRAF, CDK4, GNAQ, IGF1R
9
Show member pathways
9.9BRAF, MITF, NRAS, TIMP3
109.9CDK4, MMP2, NRAS, VEGFC
11
Show member pathways
9.9BRAF, CDK4, IGF1R, MET
12
Show member pathways
9.9CDH5, MMP2, TIMP3, VEGFC
13
Show member pathways
9.9GNAQ, MC1R, MITF, NRAS, TYR
149.9BRAF, GNA11, GNAQ, IGF1R, NRAS
159.8BRAF, CDK4, CDKN2A, IGF1R, NRAS
16
Show member pathways
9.8BRAF, CDK4, CDKN2A, MMP2, NRAS
179.8CDK4, IGF1R, MET, NRAS, VEGFC
18
Show member pathways
9.7GNA11, IGF1R, MET, NRAS, TIMP3, VEGFC
19
Show member pathways
9.7BRAF, GNAQ, IGF1R, MET, NRAS, VEGFC
209.6BRAF, IGF1R, MET, MMP2, NRAS, TIMP3
219.5BRAF, GNA11, GNAQ, IGF1R, NRAS, TIMP3
22
Show member pathways
9.5BRAF, GNA11, IGF1R, MET, NRAS, TIMP3
23
Show member pathways
9.5BRAF, CDH5, IGF1R, MET, NRAS, TIMP3
24
Show member pathways
9.4BRAF, CDK4, CDKN2A, IGF1R, MET, MITF
25
Show member pathways
9.1BRAF, CDH5, CDK4, CDKN2A, GNA11, IGF1R
26
Show member pathways
9.1BRAF, CDK4, CDKN2A, GNA11, IGF1R, MET
279.1BRAF, CDK4, CDKN2A, GNA11, GNAQ, IGF1R

GO Terms for genes affiliated with Uveal Melanoma

About this section

Biological processes related to Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1entrainment of circadian clockGO:000964911.0GNA11, GNAQ
2G-protein coupled acetylcholine receptor signaling pathwayGO:000721311.0GNA11, GNAQ
3phospholipase C-activating dopamine receptor signaling pathwayGO:006015811.0GNA11, GNAQ
4phototransduction, visible lightGO:000760311.0GNA11, GNAQ
5regulation of melanocyte differentiationGO:004563411.0GNA11, GNAQ
6blood vessel maturationGO:000195511.0CDH5, MMP2
7developmental pigmentationGO:004806610.9GNA11, GNAQ, PMEL
8pigmentationGO:004347310.8MC1R, MITF, TYR
9melanin biosynthetic processGO:004243810.8MC1R, PMEL, TYR
10signal transductionGO:00071659.2BRAF, CDK4, CYSLTR2, GNA11, GNAQ, IGF1R

Molecular functions related to Uveal Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1type 2A serotonin receptor bindingGO:003182610.3GNA11, GNAQ
2protein bindingGO:00055158.1BAP1, BRAF, CDH5, CDK4, CDKN2A, CYSLTR2

Sources for Uveal Melanoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet